WO2012148181A2 - 약물 방출제어용 조성물 - Google Patents
약물 방출제어용 조성물 Download PDFInfo
- Publication number
- WO2012148181A2 WO2012148181A2 PCT/KR2012/003223 KR2012003223W WO2012148181A2 WO 2012148181 A2 WO2012148181 A2 WO 2012148181A2 KR 2012003223 W KR2012003223 W KR 2012003223W WO 2012148181 A2 WO2012148181 A2 WO 2012148181A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- release
- drug
- weight
- composition
- parts
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Definitions
- the present invention relates to a composition for controlling drug release.
- the drug release control composition of the present invention forms a basic skeleton of the sustained release polymer of the matrix type, and expands the release control ability of the sustained release polymer as a carbomer occurs sol-gel conversion according to pH.
- the present invention is characterized in that it further contains a solubilizer to be suitable, especially when the drug to be released is highly poorly soluble and a disintegrant for sufficient initial release.
- controlled release preparations can release the drug continuously for a certain time in the body, thereby maintaining the effective blood concentration of the drug for a long time. Therefore, it is possible to reduce the amplitude of the blood concentration caused by the frequent administration of conventional formulations, thereby reducing side effects, and furthermore, there is an advantage of improving patient compliance by reducing the frequency of administration.
- sustained-release matrix tablets are mainly used in the pharmaceutical industry because they can be produced by conventional manufacturing techniques and equipment, and the drug is also eluted while the base is gradually dissolved from the outside in the gastrointestinal fluid.
- base materials include sustained-release polymers such as hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), polyvinyl alcohol (PVA), Carbopol, polyethylene oxide (PEO), and the like.
- the sustained-release matrix formulation has a problem that once the matrix structure is collapsed, the drug is rapidly released and the blood concentration is temporarily increased.
- the present invention has been made to solve the above problems, while retaining the advantages of the conventional matrix structure, it is possible to suppress the rapid release of the drug even after the collapse of the matrix structure, fully solubilizing high-soluble drugs, the initial release rate It is an object of the present invention to provide an improved new drug release control composition.
- the present invention is to provide a cilostazol sustained-release tablet that can be properly controlled by the drug release control composition to prevent side effects due to rapid release.
- composition for controlling drug release of the present invention is provided.
- the sustained-release polymer is hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), polyvinyl alcohol (PVA), Carbopol (Carbopol), polyethylene oxide (PEO) and copolymers or mixtures thereof, preferably Preferably hydroxypropylmethylcellulose (HPMC).
- HPMC hydroxypropyl cellulose
- HPMC hydroxypropyl methyl cellulose
- PVA polyvinyl alcohol
- Carbopol Carbopol
- PEO polyethylene oxide
- HPMC Preferably hydroxypropylmethylcellulose
- the viscosity of the sustained-release polymer may be 50,000 to 150,000 cps, preferably 80,000 to 120,000 cps.
- solubilizer may be sodium lauryl sulphate, Labrafil, Labrasol, Tween 60 or mixtures thereof, preferably sodium lauryl sulphate.
- the disintegrant may be crosscamellose-Na, sodium starch glycolate, pregelatinized starch, microcrystalline cellulose, crospovidone. , cross-linked povidone and other commercially available polyvinylpyrrolidone (PVP), low-substituted hydroxypropylcellulose (low substituted), alginic acid, carboxymethylcellulose, calcium salt And sodium salts, colloidal silica dioxide, guar gum, magnesium alumimum silicate, methylcellulose, powdered cellulose, starch, sodium alginate alginate) and mixtures thereof.
- PVP polyvinylpyrrolidone
- the drug may be cilostazol, levamipid, aripiprazole, irbesartan, atazanavir or labuconazole.
- the content of the drug may be 10 to 2000 parts by weight, preferably 20 to 1900 parts by weight per 100 parts by weight of the sustained release polymer.
- the drug release control composition of the present invention can prevent the rapid release of the drug due to the dissolution of the late matrix structure by introducing a carbomer having a sol-gel conversion property while retaining the sustained release of the conventional matrix structure of the sustained release polymer. have.
- the solubilizer solved the problem that the highly insoluble drug does not dissolve even after release, the disintegrating agent was introduced to improve the initial release rate which is the limit of the sustained release formulation.
- 1 is a graph showing the dissolution rate test results in the absence of a solubilizer and a disintegrant.
- Figure 2 is a graph showing the dissolution rate test results in the state containing a solubilizer.
- 3 is a graph showing the dissolution rate test results of the solubilizer and the disintegrant.
- FIG. 4 is a graph showing a nonclinical test result of the present invention containing a solubilizer and a disintegrant.
- FIG. 5 is a graph showing the results of a single clinical test of the present invention containing a solubilizer and a disintegrant.
- Figure 6 is a graph showing the dissolution rate test results of another drug containing a solubilizer and a disintegrant.
- composition for controlling drug release of the present invention is a composition for controlling drug release of the present invention.
- sustained-release polymers Preparations for delaying the dissolution of pharmacologically active ingredients are prepared by mixing sustained-release polymers.
- the sustained-release polymers may be used as long as they are pharmaceutically acceptable polymers, and methyl cellulose, ethyl cellulose, and hydropropylmethyl.
- Cellulose derivatives such as cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, propylene oxide and its derivatives, polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohol, polyvinylacetate, polyvinylacetate phthalate , Polymethacrylate and derivatives thereof, Carbopol, polyethylene oxide, glycerol monostearate, poloxamer and copolymers or mixtures thereof, preferably hydroxypropylmethylcellulose.
- hydroxypropyl methyl cellulose Preferably hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinylpyrrolidone, polyvinyl alcohol and copolymers or mixtures thereof, more preferably hydroxypropyl cellulose can be used.
- the present inventors found that, when a slow release is required, when a carbomer is mixed with a general sustained-release polymer, a long dissolution time and a constant drug dissolution pattern are shown compared with a single-release sustained-release polymer. In addition, it was found that the elution pattern can be controlled by controlling the weight ratio of the sustained-release polymer and the carbomer.
- sustained-release preparations Rapid dissolution of the drug can cause tachycardia, headache, or headache, so maintaining and controlling a constant dissolution rate is an important factor in sustained-release preparations.
- Sustained release polymers such as hydroxypropylmethylcellulose, can form a matrix to prevent rapid dissolution of pharmacologically active ingredients in tablets to ensure a long dissolution time. In addition, it shows a uniform dissolution pattern compared to other sustained-release polymers.
- the tablets expand during dissolution.
- the matrix of the sustained-release polymer is not strong, the matrix may be partially damaged and the tablets may disintegrate, which may lead to rapid drug release, causing headache or flushing in the patient.
- the present invention used a mixture of slow-release polymer and carbomer.
- Carbomer may be used alone as a sustained-release polymer, but causes sol-gel conversion according to pH, and used in combination with other sustained-release polymer in the present invention.
- the carbomer is present in a sol state in the stomach, which is an acidic condition, and drug release is maintained by the sustained release polymer.
- the sustained release polymer In the small intestine, which is an alkaline condition, the carbomer is present in a hydrogel state to control the release of the drug.
- sustained-release polymer it has the effect of strengthening the matrix in the drug, and the expansion of the tablet to maintain the form, by maintaining the matrix of the tablet to prevent the tablet from falling off to maintain a constant dissolution rate.
- the sustained release polymer used in the present invention has a viscosity of 50,000 to 150,000 cps, preferably a sustained release polymer having a viscosity of 80,000 to 120,000 cps. If the viscosity is less than 50,000 cps, a large amount of sustained-release polymer is required, and the size of the tablet becomes large. If the viscosity exceeds 150,000 cps, uniform mixing with the pharmacological components becomes difficult. Even if the viscosity is the same, the particle crushing degree is more uniform, and the physical shape of the product having excellent dispersion is used.
- the weight ratio of the sustained release polymer to the carbomer in the drug release control composition according to the present invention is preferably in the ratio of 5 to 100 parts by weight of carbomer per 100 parts by weight of the sustained release polymer. If the amount of carbomer is less than the above range, it is difficult to ensure sustained release under alkaline conditions, and if it exceeds the above range, the dissolution rate of the drug is excessively lowered under alkaline conditions, and uniform mixing between the drug and the sustained release polymer is difficult.
- the preparation including the drug release control composition according to the present invention shows a constant dissolution rate according to the change in pH.
- the formulation containing the composition for controlling drug release according to the present invention maintains a uniform dissolution rate at pH 1.2 (artificial gastric fluid) and pH 6.8 (industrial fluid).
- the drug to which the drug release control composition, such as the present invention is applied may include substances having a very low solubility, in which case the solubility of the drug is further worsened by adding to the sustained release system of the present invention. This results in a rapid release of the drug after taking it, making the initial pharmacological effect difficult to expect.
- the present invention is characterized by the addition of a solubilizer to assist in the dissolution of poorly soluble drugs to solve this problem.
- Solubilizers that can be used in the present invention can be used as long as it is a pharmaceutically acceptable solubilizer, specifically sodium lauryl sulphate, Labrafil (Labrafil), Labrasol (Labrasol), Tween 60 ) Or mixtures thereof, preferably sodium lauryl sulphate.
- the content of the solubilizer is preferably 10 to 200 parts by weight per 100 parts by weight of the sustained-release polymer, but below the above range, the drug does not reach the critical micelle concentration below the above range, thereby reducing the dissolution rate to provide sufficient pharmacological effect. On the contrary, if it exceeds the above range, there is a fear that the concentration of the free drug decreases and the absorption of the drug decreases.
- the low initial release rate described above may be attributable to the matrix structure formed by the sustained release polymer, and in order to prevent this, the release of the sustained release polymer itself may be controlled at the end of the dissolution due to the collapse of the formulation itself. It causes a number of problems. In order to solve this problem, the present invention was able to achieve the overall release control while maintaining the initial release rate over a certain level by introducing a suitable ratio of disintegrant.
- any disintegrant that can be used in the present invention can be used as long as it is a pharmaceutically acceptable solubilizer, and specifically, crosscamellose-Na, sodium starch glycolate, pregelatinized Pregelatinized Starch, microcrystalline cellulose, crospovidone, cross-linked povidone and other commercially available polyvinylpyrrolidone (PVP), low-substituted hydroxypropylcellulose (Hydroxypropylcellulose) low substituted, alginic acid, Carboxymethylcellulose, calcium and sodium salts, colloidal silica collidal silica, guar gum, magnesium aluminum silicate, Methylcellulose, powdered cellulose, starch, sodium alginate alginate) and mixtures thereof.
- a pharmaceutically acceptable solubilizer and specifically, crosscamellose-Na, sodium starch glycolate, pregelatinized Pregelatinized Starch, microcrystalline cellulose, crospovidone, cross-linked povidone and other commercially available polyviny
- the content of the disintegrant is preferably 30 to 70 parts by weight per 100 parts by weight of the sustained-release polymer, but below the above range, water does not penetrate into the tablet and cause sufficient wetting action indicated through maternal action to delay dissolution of the drug. On the contrary, if the above range is exceeded, drug release is promoted simultaneously with rapid expansion of the tablet, so that the initial drug dissolution is increased and absorption is promoted, which may cause side effects.
- the drug to be delivered through the drug release control composition of the present invention can be used without limitation as long as it is a drug that requires sustained release, and in particular, low solubility cilostazol, levamipid, aripiprazole, irbesartan, atazanavir or In the case of labuconazole, the advantages of the present invention are markedly expressed.
- the content of the drug may be 10 to 2000 parts by weight, preferably 20 to 1900 parts by weight per 100 parts by weight of the sustained release polymer.
- Drugs less than the above range may not be expected to have sufficient drug release due to a longer release time and less amount of drug released per unit time. Conversely, if the amount exceeds the above range, drug release time may be shortened and the amount of drug released per unit time may increase, causing side effects.
- the dissolution test was conducted according to the 7th Amendment Dissolution Test Method.
- PH 7.8 phosphate buffer was used as the eluent.
- the elution was performed using the paddle method, the eluent was 900 ml, the stirring speed was 100 rpm, and the elution temperature was 37 ⁇ 0.5 °C. 5 ml of the sample was taken at 0, 5, 10, 15, 30, 45, and 60 minutes, and the same amount of eluate was added.
- the binding solution was prepared by dispersing and dissolving povidone K-30 and carbomer (50%) in ethanol.
- cilostazol using a speed mixer, cilostazol, microcrystalline cellulose, carbomer (50%), and hydroxypropylmethylcellulose were mixed well, and wet granulation was performed in a cylindrical granulator using a binding solution.
- the granules thus prepared were dried at least 12 hr in a dry oven (40 ° C.), sieved through a sieve of 40 mesh, and further mixed with hard silicic anhydride and magnesium stearate in the sintered semi-finished product, followed by tableting according to the weight as described below.
- a certain amount of cilostazol sustained-release tablet prepared in the following example was eluted by the test example.
- a 0.5 W / W% sodium lauryl sulfate aqueous solution was used as the eluent.
- the elution method was paddle method, the eluent 900 ml, the stirring speed was 75 rpm, and the elution temperature was performed at 37 ⁇ 0.5 ° C.
- Cilostazol 200 40 200 38.46 200 42.55 200 33.33 Western Polymers Carbomer 50 10 70 13.46 10 4.25 50 8.33 Hydroxypropylmethylcellulose (100,000 cps) 100 20 100 19.23 100 21.27 200 33.33 Binder Povidone K-30 25 5 25 4.8 25 5.31 25 4.16 Filler Microcrystalline cellulose 100 20 100 19.23 100 21.27 100 16.66 Hard silicic anhydride 10 2 10 1.92 10 2.12 10 1.66 Lubricant Magnesium stearate 15 3 15 2.88 15 3.19 15 2.5 1 tablet gross weight 500 100 520 100 470 100 600 100
- the dissolution test was performed by the 7th Amendment Dissolution Test Method of the Korean Pharmacopoeia, and the test solution was used at 900 ml of sodium lauryl sulfate (0.5%) solution for 50 revolutions per minute according to the Dissolution Test Method No. 2 of the Pharmacopoeia Test Method. Tested at 37 ⁇ 0.5 ° C. Eluate 5 from each vessel at 0, 15, 30, 60, 90, 120, 180, 300, 360, 480, 600, 720, 840, 960, 1080, 1220, 1440 min. ML was taken and filtered with a 0.45 ⁇ m membrane filter, and the solution was used as a sample solution. The samples and standard solutions were measured for absorbance At and As at wavelength 257 nm using UV (spectrophotometer, Shimadzu, Japan). The dissolution results are shown in FIG.
- the prepared tablets were measured for the degree of fluidity through the angle of repose, and the hardness was measured to determine their suitability. Then, dissolution test was performed as in Test Example and Example 1, and the results are shown in FIG.
- Cilostazol 200 Carbomer 5 Hydroxypropylmethylcellulose 15 Sodium lauryl sulfate 20 Croscarmellose sodium 5 Povidone K-30 6 Microcrystalline cellulose 115 Hard silicic anhydride 10 Magnesium Stearate 8
- Example 2 and the control material were orally administered to beagle dogs and then nonclinical tests were performed to determine the in vivo kinetics of the drug.
- Example 2 and one tablet of the control material were orally administered to the beagle dog, and blood samples were collected at a predetermined time, and then plasma was separated, and then the concentration of cilostazol in the beagle dog plasma was measured.
- the pharmacokinetic parameters were calculated using the BA Calc 2007 program: AUCt (Blood-Time Curve Area from Dosing Time to Final Blood Level Time t), AUCi (Blood-Time Curve Area from Dose Time to Infinite Time) , Cmax (highest blood concentration), Tmax (highest blood concentration attainment time) and t1 / 2 (blood loss half-life) were calculated.
- AUCi / dose and Cmax / dose were expressed by calculating AUCi and Cmax divided by the dose, respectively, and the ratio of AUCt and AUCi was expressed as AUCt / AUCi.
- SPSS Student t-test
- Cilostazol in Beagle shoulder plasma after test and control was detected from 1 hour after the first blood collection and 5 of 6 test groups were detected by 36 hours, and 1 of 6 control groups. Up to 36 hours, two were detected up to 24 hours, the other three were detected only up to 12 hours.
- the AUCt / AUCi of the Example 2 administration group and the control group administration group was 0.949 and 0.924, respectively, and it was found that cilostazol in plasma lost 94.9 and 92.4% in 36 hours after drug administration, respectively.
- Example 2 AUCi / dose was 3.60 and 3.34 hr * ng / mL, Cmax / dose was 0.62 and 0.87 ng / mL, Tmax was 4.17 and 2.75 hr, and t1 / 2 was 8.34 and 7.25 hr, respectively. .
- Example 2 The AUCi / dose ratio was 108.0% and the Cmax / dose ratio was 71.7% between the administration group and the control group.
- P-values of pharmacokinetic parameters were 0.530 (AUCi / dose), 0.071 (Cmax / dose), 0.001 (Tmax) and 0.690 (t1 / 2).
- Example 2 and the control did not find significant differences in AUCi / dose, Cmax / dose and t1 / 2, but showed a significant difference in Tmax. Therefore, Example 2 is considered to have a pharmacokinetic difference from the control, and cilostazol in plasma showed a similar tendency up to 3 hours after administration when comparing the average concentration of Example 2 with the control group. After that, it could be confirmed that the Example 2 administration group was maintained at a higher concentration than the control substance administration group.
- Test Example 3 Single clinical test
- Test drug fasting: before each dose (0h), 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 60, 72hr (14 times in total)
- the pattern of adverse events was compared using Fisher's exact test and non-parametric comparison method (Mann-Whitney U test) by order group, treatment group and time of administration. Other safety assessment items were reviewed for individual values.
- Adverse reaction Observe the subjective symptoms or the subjective symptoms.
- Hematology Hemoglobin, Hematocrit, RBC, WBC (Leucocytes), Neutrophils, Eosinophils, Basophils, Lymphocytes, Monocytes, Platelet
- Blood chemistry Creatinine, Total protein, Albumin, sGOT (AST), sGPT (ALT), Total bilirubin, Glucose (fast), Total cholesterol, Alkaline phophatase (ALP), BUN, Ca, P, Gamma GT, Triglyceride, HDL-Cholesterol, LDL-Cholesterol, Uric acid, LDH
- Urine test Specific gravity, Color, pH, Glucose, Albumin,
- Pharmacokinetic parameters are calculated after drug concentration analysis, and the primary endpoints of the reference drug (fasting) and the test drug (fasting) for Cmax and AUC72h, which are the primary endpoints.
- Cilostazol immediate release and two types of cilostazol and active metabolites in blood over 72 hours after administration (OPC-13015; 3,4-dehydro-cilostazol, OPC-13213; 4'-trans-hydroxy-cilostazol) Measure the concentration of Treatment and analysis of clinical samples is performed using LC-MS / MS according to the analysis conditions established by the laboratory of Hopkins Bio Research Center, Inc. The established analytical methods are applied to sample analysis after validation for specificity, linearity, accuracy, precision and sensitivity, and the following pharmacokinetic items are evaluated.
- a therapy was administered as a control regimen with a single tablet of pretal tablet (Cilostazol 100 mg) twice a day after a meal, and in B therapy, Example 2
- the cilostazol sustained-release tablet (Cilostazol 200 mg) was administered once a day after a meal, but set a 7 day washout period.
- AUC ⁇ was 8956 ⁇ 2440 ⁇ g / L * hr and Cmax was 625.01 ⁇ 168.
- ⁇ g / L and the coefficients of variation were 27.2% and 26.9%, respectively, and the total number of subjects that can be confirmed with 80% power when the difference between the Example and the control material differed by more than 20% at the significance level of 0.05 was 13 per group. Total 26 people. In this study, 3 patients were added to each group considering the number of dropouts, and a total of 32 subjects were tested.
- Cmax and AUC are 1414.55 ng / mL for cilostazol, 24738.45 hr-ng / mL, 259.463 ng / mL for OPC-13015, 7107.002 hr-ng / mL, 120.872 ng / mL for OPC-13213, 2363.514, respectively.
- Example 3 Formulations Added Solubilizer and Disintegrant (2, 3)
- the excipients were sufficiently mixed with levamipid and ariferrazole in the mixing ratios of Table 7, and in addition to the polymer base, HPMC And then mixed in a powder mixer to uniformly prepare a wet granules with ethanol. Typically 10 ml of ethanol was used to prepare 100 tablets. If necessary, a small amount of the polymer base in the formulation can be dissolved in a mixed solvent of water or alcohol and used to granulate the powder. The granules prepared are sufficiently dried in an oven at 60 ° C.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
분류 | 성분 | 처방 1 | 처방 2 | 처방 3 | 처방 4 | ||||
함량(mg) | 함량비(%) | 함량(mg) | 함량비(%) | 함량(mg) | 함량비(%) | 함량(mg) | 함량비(%) | ||
약리학적유효성분 | 실로스타졸 | 200 | 40 | 200 | 38.46 | 200 | 42.55 | 200 | 33.33 |
서방용고분자 | 카보머 | 50 | 10 | 70 | 13.46 | 10 | 4.25 | 50 | 8.33 |
히드록시프로필메틸셀룰로스(100,000 cps) | 100 | 20 | 100 | 19.23 | 100 | 21.27 | 200 | 33.33 | |
결합제 | 포비돈 K-30 | 25 | 5 | 25 | 4.8 | 25 | 5.31 | 25 | 4.16 |
충진제 | 미결정 셀룰로스 | 100 | 20 | 100 | 19.23 | 100 | 21.27 | 100 | 16.66 |
경질 무수규산 | 10 | 2 | 10 | 1.92 | 10 | 2.12 | 10 | 1.66 | |
활택제 | 스테아린산마그네슘 | 15 | 3 | 15 | 2.88 | 15 | 3.19 | 15 | 2.5 |
1정 총중량 | 500 | 100 | 520 | 100 | 470 | 100 | 600 | 100 |
성분 | 함량(mg) | 함량비(%) |
실로스타졸 | 200 | 52.77 |
카보머 | 3 | 0.79 |
히드록시프로필메틸셀룰로스 | 13 | 3.43 |
소듐 라우릴설페이트 | 20 | 5.28 |
크로스카멜로스 소듐 | 4 | 1.06 |
포비돈 K-30 | 6 | 1.58 |
미결정 셀룰로스 | 115 | 30.34 |
경질 무수규산 | 10 | 2.64 |
스테아린산 마그네슘 | 8 | 2.11 |
1정 총중량 | 379 | 100 |
성분 | 함량(mg) |
실로스타졸 | 200 |
카보머 | 5 |
히드록시프로필메틸셀룰로스 | 15 |
소듐 라우릴설페이트 | 20 |
크로스카멜로스 소듐 | 5 |
포비돈 K-30 | 6 |
미결정 셀룰로스 | 115 |
경질 무수규산 | 10 |
스테아린산 마그네슘 | 8 |
대조물질 | 실시예 2 | |
Cmax /dose (ng/mL) | 0.87 ± 0.28 | 0.62 ± 0.12 |
Tmax (h) | 2.75 ± 0.61 | 4.17 ± 0.41 |
T1/2 (h) | 7.25 ± 6.18 | 8.34 ± 1.56 |
AUCt (hng/mL) | 307.63 ± 86.14 | 683.77 ± 90.68 |
AUC∞ (hng/mL) | 333.72 ± 88.73 | 720.93 ± 95.01 |
AUC(0-t)/AUC(0-inf),% | 92.41 ± 7.59 | 94.88 ± 3.28 |
F* (%) | - | 108.0 |
순서시험군 | 피험자수 | 시험요법 | |
제1기 | 제2기 | ||
Ⅰ | 16 명 | A | B |
Ⅱ | 16 명 | B | A |
약물동력학적변수 | 실로스타졸 | OPC-13015 | OPC-13213 | |||
대조물질 | 실시예2 | 대조물질 | 실시예2 | 대조물질 | 실시예2 | |
Cmax (μg/mL) | 1413.052 | 1414.551 | 297.159 | 259.463 | 145.438 | 120.872 |
AUC∞ (hμg/mL) | 26482.49 | 24738.445 | 7833.247 | 7107.002 | 2889 | 2363.514 |
성분 | 함량(mg) | |
레바미피드 | 300 | - |
아리피페라졸 | 5 | |
카보머 | 10 | 3 |
히드록시프로필메틸셀룰로스 | 28 | 10 |
소듐 라우릴설페이트 | 5 | 5 |
크로스카멜로스 소듐 | 15 | 4 |
포비돈 K-30 | 10 | 9 |
미결정 셀룰로스 | 100 | 60 |
경질 무수규산 | - | 2 |
스테아린산 마그네슘 | 12 | 2 |
Claims (7)
- 서방용 고분자 100 중량부,카보머(Carbomer) 5 내지 100 중량부,가용화제 10 내지 200 중량부, 및붕해제 30 내지 70 중량부를 포함하는 약물 방출제어용 조성물.
- 청구항 1에 있어서,상기 서방용 고분자는 히드록시프로필셀룰로오스(HPC), 히드록시프로필메틸셀룰로오스(HPMC), 폴리비닐알코올(PVA), 카보폴(Carbopol), 폴리에틸렌옥사이드(PEO) 및 그 공중합체나 혼합물인 것을 특징으로 하는 약물 방출제어용 조성물.
- 청구항 2에 있어서,상기 서방용 고분자의 점도는 50,000 내지 150,000 cps인 것을 특징으로 하는 약물 방출제어용 조성물.
- 청구항 1에 있어서,상기 가용화제는 소듐 라우릴 셀페이트, 라브라필(Labrafil), 라브라졸(Labrasol), 트윈 60 (Tween 60) 및 그 혼합물로 이루어진 군에서 선택된 것을 특징으로 하는 약물 방출제어용 조성물.
- 청구항 1에 있어서,상기 붕해제는 크로스카멜로스-소듐 (Crosscamellose-Na), 소듐 스타치 글리콜레이트 (Sodium starch glycolate), 프리젤라틴화 스타치 (Pregelatinized Starch), 미세결정 셀룰로오즈 (microcrystalline cellulose), 크로스포비돈 (Crospovidone, cross-linked povidone)과 기타 상업적으로 유용한 폴리비닐피롤리돈(Polyvinylpyrrolidone, PVP), 저치환 히드록시프로필셀룰로오스 (Hydroxypropylcellulose, low substituted), 알긴산 (alginic acid), 카르복시메틸셀룰로오즈 (Carboxymethylcellulose), 칼슘염 및 소듐염, 콜로이드성 이산화규소 (Fumed silica collidal silica), 구아검 (guar gum), 마그네슘 알루미늄 실리케이트 (Magnesium alumimum silicate), 메틸셀룰로오즈 (methylcellulose), 분말성 셀룰로오즈, 전분(starch), 소듐 알지네이트 (sodium alginate) 및 그 혼합물로 구성된 군에서 선택된 것을 특징으로 하는 약물 방출제어용 조성물.
- 청구항 1에 있어서,상기 약물은 실로스타졸, 레바미피드, 아리피페라졸, 이르베사르탄, 아타자나비어 또는 라부코나졸인 것을 특징으로 하는 약물 방출제어용 조성물.
- 청구항 1에 있어서,상기 약물의 함량은 서방용 고분자 100 중량부 당 10 내지 2000 중량부인 것을 특징으로 하는 약물 방출제어용 조성물.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110041150A KR20130106456A (ko) | 2011-04-29 | 2011-04-29 | 약물 방출제어용 조성물 |
KR10-2011-0041150 | 2011-04-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012148181A2 true WO2012148181A2 (ko) | 2012-11-01 |
WO2012148181A3 WO2012148181A3 (ko) | 2012-12-20 |
Family
ID=47072908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/003223 WO2012148181A2 (ko) | 2011-04-29 | 2012-04-26 | 약물 방출제어용 조성물 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20130106456A (ko) |
WO (1) | WO2012148181A2 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114404379A (zh) * | 2022-01-29 | 2022-04-29 | 杭州沐源生物医药科技有限公司 | 一种瑞巴派特缓释片及其制备方法 |
WO2024037982A1 (en) * | 2022-08-16 | 2024-02-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations of nintedanib for intraocular use |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2907508A1 (en) * | 2014-02-14 | 2015-08-19 | Shin-Etsu Chemical Co., Ltd. | Hydroxyalkylalkyl cellulose for tableting and solid preparation comprising the same |
KR101748215B1 (ko) * | 2015-05-29 | 2017-06-20 | 한국유나이티드제약 주식회사 | 경구용 서방성 제제 |
KR20180058644A (ko) * | 2016-11-24 | 2018-06-01 | 에스케이케미칼 주식회사 | 바레니클린 서방성 제제 및 이의 제조 방법 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7144585B1 (en) * | 1999-03-25 | 2006-12-05 | Otsuka Pharmaceutical Co., Ltd. | Cilostazol preparation |
KR20070024254A (ko) * | 2005-08-26 | 2007-03-02 | 한국오츠카제약 주식회사 | 실로스타졸 함유 서방정 |
KR20070118444A (ko) * | 2006-06-12 | 2007-12-17 | 신풍제약주식회사 | 록소프로펜 또는 잘토프로펜 함유 제어방출성 제제 및 그의제조방법 |
KR20100027337A (ko) * | 2008-09-02 | 2010-03-11 | 한국유나이티드제약 주식회사 | 용출률 향상과 부작용 발현이 최소화된 실로스타졸 서방정 |
US20110014282A1 (en) * | 2008-02-28 | 2011-01-20 | De Vasconcelos Teofilo Cardoso | Pharmaceutical composition for poorly soluble drugs |
KR20110132170A (ko) * | 2010-06-01 | 2011-12-07 | 한국유나이티드제약 주식회사 | 1일 1회 투여로 최적의 약리학적 임상 효과를 제공하는 아세클로페낙 서방성 제제 |
-
2011
- 2011-04-29 KR KR1020110041150A patent/KR20130106456A/ko active Application Filing
-
2012
- 2012-04-26 WO PCT/KR2012/003223 patent/WO2012148181A2/ko active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7144585B1 (en) * | 1999-03-25 | 2006-12-05 | Otsuka Pharmaceutical Co., Ltd. | Cilostazol preparation |
KR20070024254A (ko) * | 2005-08-26 | 2007-03-02 | 한국오츠카제약 주식회사 | 실로스타졸 함유 서방정 |
KR20070118444A (ko) * | 2006-06-12 | 2007-12-17 | 신풍제약주식회사 | 록소프로펜 또는 잘토프로펜 함유 제어방출성 제제 및 그의제조방법 |
US20110014282A1 (en) * | 2008-02-28 | 2011-01-20 | De Vasconcelos Teofilo Cardoso | Pharmaceutical composition for poorly soluble drugs |
KR20100027337A (ko) * | 2008-09-02 | 2010-03-11 | 한국유나이티드제약 주식회사 | 용출률 향상과 부작용 발현이 최소화된 실로스타졸 서방정 |
KR20110132170A (ko) * | 2010-06-01 | 2011-12-07 | 한국유나이티드제약 주식회사 | 1일 1회 투여로 최적의 약리학적 임상 효과를 제공하는 아세클로페낙 서방성 제제 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114404379A (zh) * | 2022-01-29 | 2022-04-29 | 杭州沐源生物医药科技有限公司 | 一种瑞巴派特缓释片及其制备方法 |
CN114404379B (zh) * | 2022-01-29 | 2024-01-26 | 杭州沐源生物医药科技有限公司 | 一种瑞巴派特缓释片及其制备方法 |
WO2024037982A1 (en) * | 2022-08-16 | 2024-02-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations of nintedanib for intraocular use |
Also Published As
Publication number | Publication date |
---|---|
WO2012148181A3 (ko) | 2012-12-20 |
KR20130106456A (ko) | 2013-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU748209B2 (en) | Novel suppository form comprising an acid-labile active compound | |
WO2018070671A1 (ko) | 레날리도마이드의 경구용 정제 조성물 | |
EP3120871B1 (en) | Solid dispersion | |
WO2020040438A1 (ko) | 에스오메프라졸 및 탄산수소나트륨을 포함하는 우수한 방출특성을 갖는 약제학적 제제 | |
SK286625B6 (sk) | Farmaceutický prípravok na báze omeprazolu | |
KR20100052453A (ko) | 타달라필 함유 약제의 제조방법 | |
WO2012148181A2 (ko) | 약물 방출제어용 조성물 | |
WO2013058450A1 (ko) | 안정화된 에페리손 의약 조성물 및 이를 함유하는 서방성 제제 | |
WO2011152652A2 (ko) | 1일 1회 투여로 최적의 약리학적 임상 효과를 제공하는 아세클로페낙 서방성 제제 | |
WO2019004770A9 (ko) | 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법 | |
WO2022103233A1 (ko) | 라베프라졸 및 제산제를 포함하는 약제학적 복합제제 및 이의 제조방법 | |
WO2019199133A1 (ko) | 레날리도마이드의 경구용 코팅 정제 조성물 | |
WO2013032206A1 (ko) | 이토프라이드 염산염을 함유하는 제어 방출성 경구 제제의 조성물 및 그의 제조방법 | |
WO2020022824A1 (ko) | 에독사반을 포함하는 약학적 제제 및 이의 제조방법 | |
WO2013157841A1 (ko) | 레보드로프로피진 함유 서방정 및 이의 제조방법 | |
WO2022075760A1 (ko) | 아프레밀라스트를 함유하는 약학 조성물 | |
WO2016122226A2 (en) | A pharmaceutical composition for treating gastrointestinal diseases | |
WO2019199132A1 (ko) | 다양한 용량의 레날리도마이드의 경구용 정제 조성물 | |
WO2016137266A2 (ko) | 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물 | |
WO2019107989A1 (ko) | 피마살탄을 포함하는 고체 분산체 | |
WO2020017808A1 (ko) | 날푸라핀 함유 구강붕해정 | |
WO2018088830A1 (en) | A pharmaceutical composition in a monolithic matrix tablet form comprising chlorthalidone or its salt and amlodipine or its salt and a process for preparing the same | |
KR20130142094A (ko) | 약물 방출제어용 조성물 | |
WO2016195377A2 (ko) | 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법 | |
WO2018097426A1 (ko) | 덱스란소프라졸을 포함하는 경구용 정제 조성물, 이를 포함하는 경구용 정제 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12777014 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013027844 Country of ref document: BR |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12777014 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 112013027844 Country of ref document: BR Kind code of ref document: A2 Effective date: 20131029 |